登录 | 注册    关注公众号  
微信公众号
搜索
 > 【HMGB1】

HMGB1信息

英文名称:High Mobility Group Protein B1
中文名称:高迁移率族蛋白B1
靶点别称:FM1 Gene Product,HMG 1 Protein,HMG-1 Protein,HMG1,Heparin-Binding Protein p30,High Mobility Group Box 1,High-Mobility Group (Nonhistone Chromosomal) Protein 1,High Mobility Group Protein B1,High Mobility Group Protein 1,HMG-1,Sulfoglucuronyl Carbohydrate Binding Protein,Amphoterin,Box Protein 1, High Mobility Group,SBP-1,High-Mobility Group Box 1,DKFZp686A04236,HMGB1
上市药物数量:0
临床药物数量:2
最高研发阶段:临床一期

HMGB1分子别名

HMGB1,HMG1,HMG3,SBP-1

HMGB1分子背景

High-mobility group protein B1 (HMGB1) is also known as high-mobility group protein 1 (HMG-1) and amphoterin, is a member of the HMGB family consisting of three members, HMGB1, HMGB2 and HMGB3. HMGB1 is a non-histone architectural chromosomal protein ubiquitously present in all vertebrate nuclei and binds double-stranded DNA without sequence specificity. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. This positions HMGB1 at the intersection of sterile and infectious inflammatory responses. HMGB1 has been studied as a DNA vaccine adjuvant and a target for cancer therapy.

HMGB1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Dociparstat sodium ODSH; CX-01; PGX-100; PGX-ODSH-2013-AML-1 临床一期 Paringenix 新型冠状病毒感染, 胰腺癌, 骨髓增生异常综合征, 蛋白丢失性肠病, 慢性阻塞性肺疾病, 急性髓细胞样白血病, 急性肺损伤 详情
SB-17170 SB-17170 临床一期 Spark Biopharma Inc 实体瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定